Skadden Advises Endo On $223M HealthTronics Deal

Law360, New York (May 6, 2010, 3:22 PM EDT) -- Continuing its push into the urological health market, Endo Pharmaceuticals Inc. announced that it had agreed to buy HealthTronics Inc. in an approximately $223 million all-cash deal.

The deal, announced Wednesday as part of a pair of transactions, will see Endo pay $4.85 for each share of HealthTronics stock plus take on about $35 million in HealthTronics existing debt.

But the price is worth it, Endo said, because the HealthTronics deal will expand its offerings to urologists with the addition of lithotripsy, benign prostate hyperplasia and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.